Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents for Primary PCI: A Subgroup Analysis of the BIOSTEMI Randomized Trial.

Juan F. Iglesias,Olivier Muller,Sylvain Losdat,Marco Roffi,David J. Kurz,Daniel Weilenmann,Christoph Kaiser,Marco Valgimigli,Stephan Windecker,Thomas Pilgrim

Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents for Primary PCI: A Subgroup Analysis of the BIOSTEMI Randomized Trial.

2020

Juan F. Iglesias
Olivier Muller
Sylvain Losdat
Marco Roffi
David J. Kurz
Daniel Weilenmann
Christoph Kaiser
Marco Valgimigli
Stephan Windecker
Thomas Pilgrim

Biodegradable polymer sirolimus-eluting stents (BP-SES) are superior to durable polymer everolimus-eluting stents (DP-EES) with respect to target lesion failure (TLF) at 1 year in patients with ST-segment elevation myocardial infarction (STEMI) ([1][1]). Beyond the biodegradable polymer, BP-SES

Keywords:

Subgroup analysis
in patient
Drug
Myocardial infarction
Randomized controlled trial
Target lesion
Biodegradable polymer
Conventional PCI
Medicine
Surgery

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations